Clofarabine Busulfan Conditioning Improves Outcomes in Patients with Active Acute Myelogenous Leukemia Undergoing Allogeneic Stem Cell Transplant
Alexis Zebrowski(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Jennifer Pinto‐Martin(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Jacqueline Smith(Roslin Institute), Alison W. Loren(University of Pennsylvania), Alexandra L. Hanlon(Virginia Tech), Ran Reshef(Abramson Cancer Center), Elizabeth O. Hexner(University of Pennsylvania), Selina M. Luger(University of Pennsylvania), David Porter(University of Pennsylvania), James K. Mangan(UC San Diego Health System)
Cited by 5
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k